Scarica l'app Stockscreener
449.74
2.19%
-10.07
Dopo l'orario di chiusura:
447.35
-2.39
-0.53%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$459.81
Aprire:
$459.57
Volume 24 ore:
364.53K
Relative Volume:
1.12
Capitalizzazione di mercato:
$10.39B
Reddito:
$1.13B
Utile/perdita netta:
$-309.44M
Rapporto P/E:
-35.14
EPS:
-12.8001
Flusso di cassa netto:
$-275.41M
1 W Prestazione:
-4.67%
1M Prestazione:
-15.00%
6M Prestazione:
-14.30%
1 anno Prestazione:
+1.72%
Intervallo 1D:
$446.61
$462.62
Intervallo di 1 settimana:
$446.61
$478.85
Portata 52W:
$393.61
$615.00
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Nome
Madrigal Pharmaceuticals Inc
Settore
Industria
Telefono
404-380-9263
Indirizzo
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
449.74 | 10.39B | 1.13B | -309.44M | -275.41M | -12.80 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-09-24 | Ripresa | Goldman | Buy |
| 2026-09-23 | Iniziato | Citigroup | Buy |
| 2026-08-04 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2026-07-27 | Iniziato | Wells Fargo | Overweight |
| 2026-01-28 | Iniziato | Barclays | Overweight |
| 2026-01-06 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-11-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2025-11-03 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2025-10-15 | Iniziato | Truist | Buy |
| 2025-09-04 | Ripresa | H.C. Wainwright | Buy |
| 2025-02-28 | Aggiornamento | B. Riley Securities | Neutral → Buy |
| 2025-02-27 | Reiterato | H.C. Wainwright | Buy |
| 2024-06-28 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-06-11 | Iniziato | Wolfe Research | Outperform |
| 2024-04-22 | Iniziato | BofA Securities | Underperform |
| 2024-03-15 | Aggiornamento | B. Riley Securities | Sell → Neutral |
| 2024-03-06 | Iniziato | Citigroup | Buy |
| 2024-02-26 | Downgrade | B. Riley Securities | Neutral → Sell |
| 2022-12-20 | Reiterato | Oppenheimer | Outperform |
| 2022-12-19 | Reiterato | H.C. Wainwright | Buy |
| 2022-12-19 | Reiterato | Piper Sandler | Overweight |
| 2022-12-19 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2022-07-08 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2021-10-07 | Iniziato | Jefferies | Buy |
| 2021-08-06 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-05-20 | Ripresa | Goldman | Buy |
| 2020-11-24 | Ripresa | Evercore ISI | Outperform |
| 2020-11-06 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-31 | Iniziato | Piper Sandler | Overweight |
| 2020-06-05 | Iniziato | BMO Capital Markets | Market Perform |
| 2020-05-05 | Iniziato | Chardan Capital Markets | Buy |
| 2020-01-30 | Iniziato | Canaccord Genuity | Buy |
| 2020-01-09 | Aggiornamento | UBS | Neutral → Buy |
| 2019-11-07 | Reiterato | H.C. Wainwright | Buy |
| 2019-06-25 | Iniziato | Stifel | Hold |
| 2019-06-10 | Aggiornamento | B. Riley FBR | Neutral → Buy |
| 2019-02-28 | Reiterato | H.C. Wainwright | Buy |
| 2019-02-22 | Iniziato | SVB Leerink | Outperform |
| 2019-01-23 | Iniziato | UBS | Neutral |
| 2018-12-14 | Iniziato | Wolfe Research | Outperform |
| 2018-12-12 | Iniziato | B. Riley FBR | Neutral |
| 2018-11-19 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2018-11-16 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2018-09-04 | Iniziato | Citigroup | Buy |
| 2018-08-06 | Downgrade | Goldman | Buy → Neutral |
| 2018-06-28 | Iniziato | Raymond James | Mkt Perform |
Mostra tutto
Madrigal Pharmaceuticals Inc Borsa (MDGL) Ultime notizie
Can NVO's Semaglutide Push Create Growth Beyond Cardiometabolic Care? - Zacks Investment Research
Madrigal Pharmaceuticals stock gets fresh Rezdiffra data - AD HOC NEWS
A liver drug improved disease measures across several genetic risk groups - Stock Titan
Under an automatic trading plan, director Paul Friedman proposes to sell shares in Madrigal Pharmaceuticals (MDGL). - Stock Titan
Madrigal Grants Equity Awards to 27 New Employees - MyChesCo
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Understanding Momentum Shifts in (MDGL) - Stock Traders Daily
Madrigal Pharmaceuticals (NASDAQ: MDGL) insider plans another stock sale after recent multimillion-dollar trades - stocktitan.net
Madrigal Pharma CEO William John Sibold disposes of common shares worth $4.16 million - Bitget
Madrigal Pharmaceuticals, Inc. Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Madrigal at cantor healthcare conference: growth, access and pipeline By Investing.com - Investing.com Nigeria
Madrigal at cantor healthcare conference: growth, access and pipeline By Investing.com - Investing.com Canada
Madrigal at cantor healthcare conference: growth, access and pipeline - investing.com
Madrigal at cantor healthcare conference: growth, access and pipeline By Investing.com - Investing.com UK
Institutional Investors Are Loading Up on Madrigal Pharmaceuticals Stock. Should You? - Yahoo Finance
Madrigal Pharmaceuticals, Inc. Rings the Closing Bell - Nasdaq
Madrigal Pharmaceuticals (NASDAQ: MDGL) exec plans $3.4M stock sale for tax withholding - stocktitan.net
September 2026 Nasdaq Stock Market Bell Ceremonies - Nasdaq
Madrigal Pharmaceuticals (MDGL) Stock Analysis: A 25% Upside Potential In Biotech Innovation - DirectorsTalk Interviews
Madrigal to Put MASH Drug Strategy Before Investors at Cantor - MyChesCo
Madrigal Pharmaceuticals (MDGL) Leads Healthcare CapEx Growth Am - GuruFocus
Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference - manilatimes.net
Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference - GlobeNewswire
Madrigal Pharmaceuticals to Participate in the 2026 Cantor Global Healthcare Conference - Yahoo Finance
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: A 27% Upside Potential Amid Biotech Innovation - DirectorsTalk Interviews
Madrigal Grants Stock Awards to 13 New Employees - MyChesCo
Here's Exactly What It Will Take for Madrigal Pharmaceuticals Stock to Take Off - Yahoo Finance
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Report: Analysts See 31% Upside Potential with Strong Buy Ratings - DirectorsTalk Interviews
When Will Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Become Profitable? - 富途牛牛
Madrigal Pharmaceuticals' General Counsel Executes Automatic Sale of 664 Shares to Cover Tax Withholding - Kalkine Media
Shannon Kelley Sells 664 Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock - MarketBeat
Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule - TradingView
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Madrigal (NASDAQ: MDGL) GC has 664 shares sold for RSU taxes - stocktitan.net
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Madrigal (NASDAQ: MDGL) officer plans $337K sell-to-cover trade - stocktitan.net
Madrigal Pharmaceuticals (MDGL) Stock May Look Cheap On Sales But Risky On Cash Flow - simplywall.st
Exploring 3 High Growth Tech Stocks In The US Market - Sahm
Madrigal Adds J&J R&D Chief to Board as MASH Push Expands - MyChesCo
Madrigal (NASDAQ: MDGL) awards Reed 647 RSUs and options on 1,078 shares - stocktitan.net
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: A Biotech Powerhouse with 33.59% Upside Potential - DirectorsTalk Interviews
2,410 Shares in Madrigal Pharmaceuticals, Inc. $MDGL Acquired by State of Wyoming - MarketBeat
Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands - MarketBeat
Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands - Yahoo Finance
Madrigal Uses Equity Awards to Recruit 10 Employees - MyChesCo
Madrigal Pharmaceuticals Inc (0JXI) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
Madrigal Pharmaceuticals Adds Renowned Leader to Board - The Globe and Mail
Dimensional Fund Advisors LP Has $4.46 Million Stock Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal Pharmaceuticals Appoints Dr. John C. Reed to Expanded Board with Detailed Compensation Plan - Kalkine Media
Madrigal Pharmaceuticals Inc Azioni (MDGL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Madrigal Pharmaceuticals Inc Azioni (MDGL) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Sibold William John | President and CEO |
Sep 11 '26 |
Sale |
542.39 |
5,221 |
2,831,801 |
197,746 |
| WILLIAM SIBOLD | Director |
Sep 11 '26 |
Proposed Sale |
533.12 |
5,221 |
2,783,420 |
0 |
| William John Sibold | Officer and Director |
Sep 09 '26 |
Proposed Sale |
534.16 |
6,362 |
3,398,326 |
0 |
| Sibold William John | President and CEO |
Sep 09 '26 |
Sale |
535.59 |
6,362 |
3,407,397 |
202,967 |
| Kelley Shannon T | General Counsel |
Aug 17 '26 |
Sale |
514.97 |
664 |
341,940 |
11,474 |
| Shannon Kelley | Officer |
Aug 17 '26 |
Proposed Sale |
507.56 |
664 |
337,020 |
0 |
| Sibold William John | President and CEO |
Jul 20 '26 |
Sale |
547.30 |
2,500 |
1,368,253 |
209,329 |
| William Sibold | Officer and Director |
Jul 20 '26 |
Proposed Sale |
553.48 |
2,500 |
1,383,700 |
0 |
| Soergel David | Chief Medical Officer |
Jun 01 '26 |
Sale |
495.74 |
1,042 |
516,561 |
10,033 |
| DAVID SOERGEL | Officer |
Jun 01 '26 |
Proposed Sale |
497.27 |
1,042 |
518,155 |
0 |
2.44%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):